Skip to content

Study · Animal study (in vivo) · mouse · 2025

4 results

Abaloparatide increases bone mass without affecting growth of bone-disseminated cancer cells.

Kane JF, Joseph GJ, Vecchi LA 3rd, Miller JS, Ludington BT, Gibson-Corley KN, Johnson RW

JBMR plus2 May 2025Cited by 4 (Europe PMC)

PMID40584157 (opens in a new tab)PMCIDPMC12204818 (opens in a new tab)DOI10.1093/jbmrpl/ziaf080 (opens in a new tab)PepBankPUB-40584157
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice inoculated with triple negative breast cancer cells, intermittent abaloparatide increased trabecular bone volume.

    In plain wordsIn mice with triple negative breast cancer cells, abaloparatide increased spongy bone volume.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular bone volume in triple negative model
    Study

    mousen: not reported in source

    breast cancer cells disseminated to bone marrow
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, we present the first evaluation of abaloparatide in preclinical models of breast cancer cells disseminated to the bone marrow and demonstrate that intermittent abaloparatide dramatically increases trabecular bone volume in mice inoculated with triple negative breast cancer cells.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In an estrogen receptor positive breast cancer model, abaloparatide increased BMD despite estradiol-associated elevation of baseline bone volume.

    In plain wordsIn mice with estrogen receptor positive breast cancer, abaloparatide increased bone density despite higher baseline bone volume from estradiol.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBMD in estrogen receptor positive model
    Study

    mousen: not reported in source

    breast cancer cells disseminated to bone marrow
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Abaloparatide also increases BMD in a model of estrogen receptor positive breast cancer, despite elevated baseline bone volume due to estradiol supplementation.
    1 context sentence
    Summary · context
    In this study, we present the first evaluation of abaloparatide in preclinical models of breast cancer cells disseminated to the bone marrow and demonstrate that intermittent abaloparatide dramatically increases trabecular bone volume in mice inoculated with triple negative breast cancer cells.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In both mouse breast cancer models, abaloparatide did not increase tumor burden at bone or soft tissue sites.

    In plain wordsIn mice with breast cancer, abaloparatide did not increase tumor burden in bone or soft tissue in either model.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTumor burden
    Study

    mousen: not reported in source

    breast cancer cells disseminated to bone marrow
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, abaloparatide does not increase tumor burden or incidence in bone or soft tissue sites in either model.
    2 context sentences
    Summary · context
    In this study, we present the first evaluation of abaloparatide in preclinical models of breast cancer cells disseminated to the bone marrow and demonstrate that intermittent abaloparatide dramatically increases trabecular bone volume in mice inoculated with triple negative breast cancer cells.
    Summary · context
    Abaloparatide also increases BMD in a model of estrogen receptor positive breast cancer, despite elevated baseline bone volume due to estradiol supplementation.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In both mouse breast cancer models, abaloparatide did not increase tumor incidence at bone or soft tissue sites.

    In plain wordsIn mice with breast cancer, abaloparatide did not increase tumor occurrence in bone or soft tissue in either model.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTumor incidence
    Study

    mousen: not reported in source

    breast cancer cells disseminated to bone marrow
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Importantly, abaloparatide does not increase tumor burden or incidence in bone or soft tissue sites in either model.
    2 context sentences
    Summary · context
    In this study, we present the first evaluation of abaloparatide in preclinical models of breast cancer cells disseminated to the bone marrow and demonstrate that intermittent abaloparatide dramatically increases trabecular bone volume in mice inoculated with triple negative breast cancer cells.
    Summary · context
    Abaloparatide also increases BMD in a model of estrogen receptor positive breast cancer, despite elevated baseline bone volume due to estradiol supplementation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.